Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) Interest Expenses (2016 - 2024)

Sunshine Biopharma (SBFM) has disclosed Interest Expenses for 11 consecutive years, with -$40652.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Interest Expenses fell 235.01% year-over-year to -$40652.0, compared with a TTM value of -$40652.0 through Sep 2025, down 151.11%, and an annual FY2024 reading of $8774.0, down 93.61% over the prior year.
  • Interest Expenses was -$40652.0 for Q4 2024 at Sunshine Biopharma, down from $245.0 in the prior quarter.
  • Across five years, Interest Expenses topped out at $195630.0 in Q2 2021 and bottomed at -$40652.0 in Q4 2024.
  • Average Interest Expenses over 5 years is $36564.1, with a median of $28328.0 recorded in 2022.
  • The sharpest move saw Interest Expenses surged 1926250.0% in 2023, then tumbled 235.01% in 2024.
  • Year by year, Interest Expenses stood at $105436.0 in 2020, then crashed by 65.26% to $36630.0 in 2021, then fell by 27.53% to $26546.0 in 2022, then rose by 13.43% to $30110.0 in 2023, then crashed by 235.01% to -$40652.0 in 2024.
  • Business Quant data shows Interest Expenses for SBFM at -$40652.0 in Q4 2024, $245.0 in Q2 2024, and $49181.0 in Q1 2024.